These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 27930979)

  • 21. Small Heat Shock Proteins B1 and B6: Which One is the Most Effective Adjuvant in Therapeutic HPV Vaccine?
    Bolhassani A; Shahbazi S; Milani A; Nadji SA
    IUBMB Life; 2018 Oct; 70(10):1002-1011. PubMed ID: 30171788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses.
    Oosterhuis K; Aleyd E; Vrijland K; Schumacher TN; Haanen JB
    Hum Gene Ther; 2012 Dec; 23(12):1301-12. PubMed ID: 22971245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-tumor effects of genetic vaccines against HPV major oncogenes.
    Cordeiro MN; Paolini F; Massa S; Curzio G; Illiano E; Duarte Silva AJ; Franconi R; Bissa M; Morghen Cde G; de Freitas AC; Venuti A
    Hum Vaccin Immunother; 2015; 11(1):45-52. PubMed ID: 25483514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7.
    Oosterhuis K; Ohlschläger P; van den Berg JH; Toebes M; Gomez R; Schumacher TN; Haanen JB
    Int J Cancer; 2011 Jul; 129(2):397-406. PubMed ID: 21207427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
    Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
    Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
    Kines RC; Zarnitsyn V; Johnson TR; Pang YY; Corbett KS; Nicewonger JD; Gangopadhyay A; Chen M; Liu J; Prausnitz MR; Schiller JT; Graham BS
    PLoS One; 2015; 10(3):e0120797. PubMed ID: 25785935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania.
    Bolhassani A; Muller M; Roohvand F; Motevalli F; Agi E; Shokri M; Rad MM; Hosseinzadeh S
    Hum Vaccin Immunother; 2014; 10(12):3499-508. PubMed ID: 25668661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors.
    Diniz MO; Cariri FA; Aps LR; Ferreira LC
    Hum Gene Ther; 2013 Oct; 24(10):861-70. PubMed ID: 24007495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice.
    Qin Y; Wang XH; Cui HL; Cheung YK; Hu MH; Zhu SG; Xie Y
    Gynecol Oncol; 2005 Feb; 96(2):475-83. PubMed ID: 15661238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of T cell-mediated and humoral immunity of beta-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein.
    Smahel M; Poláková I; Pokorná D; Ludvíková V; Dusková M; Vlasák J
    Int J Oncol; 2008 Jul; 33(1):93-101. PubMed ID: 18575754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice.
    Granadillo M; Vallespi MG; Batte A; Mendoza O; Soria Y; Lugo VM; Torrens I
    Vaccine; 2011 Jan; 29(5):920-30. PubMed ID: 21145912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amino-functionalized poly(L-lactide) lamellar single crystals as a valuable substrate for delivery of HPV16-E7 tumor antigen in vaccine development.
    Di Bonito P; Petrone L; Casini G; Francolini I; Ammendolia MG; Accardi L; Piozzi A; D'Ilario L; Martinelli A
    Int J Nanomedicine; 2015; 10():3447-58. PubMed ID: 26056443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
    Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
    J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.
    Zhou L; Zhu T; Ye X; Yang L; Wang B; Liang X; Lu L; Tsao YP; Chen SL; Li J; Xiao X
    Hum Gene Ther; 2010 Jan; 21(1):109-19. PubMed ID: 19715402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants.
    Ohlschläger P; Quetting M; Alvarez G; Dürst M; Gissmann L; Kaufmann AM
    Int J Cancer; 2009 Jul; 125(1):189-98. PubMed ID: 19358269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
    Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
    Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MyD88 signal is required for more efficient induction of Ag-specific adaptive immune responses and antitumor resistance in a human papillomavirus E7 DNA vaccine model.
    Sin JI
    Vaccine; 2011 May; 29(24):4125-31. PubMed ID: 21496466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
    Nieto K; Kern A; Leuchs B; Gissmann L; Müller M; Kleinschmidt JA
    Antivir Ther; 2009; 14(8):1125-37. PubMed ID: 20032542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1.
    Lasaro MO; Diniz MO; Reyes-Sandoval A; Ertl HC; Ferreira LC
    Microbes Infect; 2005 Dec; 7(15):1541-50. PubMed ID: 16213178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.